SCHEMBL18438101

SCHEMBL18438101

c1ccc2[nH]c(-c3n[nH]c4ccc(-c5cnccn5)nc34)nc2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ METAP2 P50579 2/20 0.62
▸ CLK2 P49760 11/20 0.60
▸ CLK3 P49761 9/20 0.60
▸ DYRK1A Q13627 9/20 0.60
▸ WNT1 P04628 2/20 0.55
▸ TGFBR1 P36897 2/20 0.55
▸ FGFR1 P11362 1/20 0.50
▸ FLT1 P17948 1/20 0.50
▸ PDPK1 O15530 1/20 0.49
▸ ATR Q13535 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ LDHA P00338 1/20 0.47
▸ EPHX2 P34913 1/20 0.47
▸ NPC1 O15118 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ PKM P14618 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ MTOR P42345 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ METAP1 P53582 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18449343 0.89 CLK2 (0.58) METAP2CLK2CLK3DYRK1AWNT1
SCHEMBL18454027 0.87 CLK2 (0.56) METAP2CLK2CLK3DYRK1AWNT1
SCHEMBL18438040 0.87 METAP2 (0.59) METAP2CLK2CLK3DYRK1AWNT1
SCHEMBL18438342 0.85 CLK2 (0.83) CLK2CLK3DYRK1AWNT1TGFBR1
SCHEMBL18438355 0.83 CLK2 (0.63) CLK2CLK3DYRK1AWNT1TGFBR1
SCHEMBL18449892 0.83 CLK2 (0.59) METAP2CLK2CLK3DYRK1AWNT1
SCHEMBL20453416 0.82 CLK2 (0.64) CLK2CLK3DYRK1AWNT1TGFBR1
SCHEMBL18438234 0.82 CLK2 (0.67) CLK2CLK3DYRK1AWNT1TGFBR1
SCHEMBL18438198 0.82 CLK2 (0.64) CLK2CLK3DYRK1AWNT1TGFBR1
SCHEMBL17566747 0.81 WNT1 (0.74) METAP2CLK2CLK3DYRK1AWNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10392383-B2 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof SAMUMED, LLC (US) 2019-08-27 — — US claimed
WO-2017023989-A1 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF SAMUMED, LLC. (US) 2017-02-09 — — WO claimed
US-10392383-B2 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof SAMUMED, LLC (US) 2019-08-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10392383-B2 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof WNT1, WNT3, WNT3A METAP2 4603/4885CLK2 2158/4885CLK3 1977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback